Form 4 for PMN ProMIS Neurosciences Inc.
Accepted 2026-02-05 00:00:00 ET · period of report 2026-02-03 · accession 0001104659-26-011137 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-02-05 | 2026-02-03 | PMN | Milbury Max A. | Principal Accounting Off | A - Grant | $12.13 | +6,595 | 8,409 | +364% | +$80.0K |
| D | 2026-02-05 | 2026-02-03 | PMN | Milbury Max A. | Principal Accounting Off | A - Grant | — | +6,595 | 6,595 | New | — |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Shares | 2026-02-03 | A | A | 6,595 | $12.13 | 8,409 | D | — | — | (F1) On February 3, 2026, pursuant to a Securities Purchase Agreement entered into by the Company with selected investors, the Reporting Person acquired 6,595 of the Company's common shares, no par value (the "Common Shares") and Common Share purchase warrants (the "Common Share Warrants") to purchase 6,595 Common Shares. The purchase price was $12.13 per Common Share and Common Share Warrant. (F2) Reflects a one-for-twenty-five reverse split of the Company's Common Shares effected on November 28, 2025. |
| 2 | Derivative | Warrants to purchase Common Shares | 2026-02-03 | A | A | 6,595 | — | 6,595 | D | $14.40 · 2026-02-03 to 2031-02-03 | 6,595 Common Shares | (F1) On February 3, 2026, pursuant to a Securities Purchase Agreement entered into by the Company with selected investors, the Reporting Person acquired 6,595 of the Company's common shares, no par value (the "Common Shares") and Common Share purchase warrants (the "Common Share Warrants") to purchase 6,595 Common Shares. The purchase price was $12.13 per Common Share and Common Share Warrant. (F3) The Common Share Warrants will expire upon the earlier of (i) February 3, 2031 or (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of topline data from the cohorts treated with single ascending doses of PMN310. |